亿帆医药：PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构

证券之星05-27 11:33

证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。

投资者提问：您好，25年报提到“ 意大利子公司非索医药获得日本 PMDA 认证”，该法规是医疗器械产品的法规，难道非索有生产医疗器械类产品吗？谢谢！

亿帆医药回复：感谢您的关注与提问。PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构。谢谢！

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2638780895?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-27 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638780895","market":"fut","top_or_hot":-1,"title":"亿帆医药：PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/002019\">亿帆医药</a>(002019)05月26日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：您好，25年报提到“ 意大利子公司非索医药获得日本 PMDA 认证”，该法规是医疗器械产品的法规，难道非索有生产医疗器械类产品吗？谢谢！</p><p>亿帆医药回复：感谢您的关注与提问。PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构。谢谢！</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亿帆医药：PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亿帆医药：PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 11:33 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026052700019706.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，25年报提到“ 意大利子公司非索医药获得日本 PMDA 认证”，该法规是医疗器械产品的法规，难道非索有生产医疗器械类产品吗？谢谢！亿帆医药回复：感谢您的关注与提问。PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026052700019706.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002019","symbol_name":"亿帆医药","start_time":0,"source_url":"https://stock.stockstar.com/RB2026052700019706.shtml","article_id":"2638780895","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638780895","pubTimestamp":1779852830,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，25年报提到“ 意大利子公司非索医药获得日本 PMDA 认证”，该法规是医疗器械产品的法规，难道非索有生产医疗器械类产品吗？谢谢！亿帆医药回复：感谢您的关注与提问。PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159883":"医疗器械","002019":"亿帆医药","BK0185":"二线龙头","BK1100":"医疗保健设备","BK0197":"中小创蓝筹","BK0070":"员工持股","BK0239":"医药制造","BK1574":"生物医药B类股","09996":"沛嘉医疗-B","BK0077":"质押式回购","BK0191":"维生素","BK1583":"高瓴概念"},"translate_title":"Yifan Pharmaceutical: PMDA (Pharmaceuticals and Medical Devices Agency), the full name of which is \"Independent Administrative Legal Person Pharmaceutical and Medical Devices Comprehensive Agency\", is the Japanese Agency responsible for the technical review of drugs and Medical Devices","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1.5,"002019":1.5,"09996":1.5},"content_text":"证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，25年报提到“ 意大利子公司非索医药获得日本 PMDA 认证”，该法规是医疗器械产品的法规，难道非索有生产医疗器械类产品吗？谢谢！亿帆医药回复：感谢您的关注与提问。PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638780895","isCrawlerRequest":true}